Healthcare
BridgeBio Pharma, Inc.
BBIO$72.50-4.71%
Price is delayed.
Add to watchlist
About BridgeBio Pharma, Inc.
BridgeBio Pharma is a biotechnology company that discovers and develops medicines for rare genetic diseases. The company has several drugs in development stages, including treatments for heart problems caused by abnormal protein buildup, a metabolic disorder affecting children, and a form of dwarfism. BridgeBio works with other pharmaceutical companies and universities to research and develop these medicines, which range from pills patients can take by mouth to genetic therapies that modify how cells work.
Loading chart...
Members only
Full research is for ConvictionStocks members
Members read the rest of this page. Where we have it for this company, that is:
- What each number means, in plain English, with the Wall Street name where the two differ.
- A plain-English summary of the company.
- How many analysts cover it, and the count behind each rating.
- Recent news, dated.
Get the free weekly market digest
The week's biggest movers, every Sunday. No spam.
Look up another company
Related Research
More Healthcare stocks to explore